You are here
IMMURX LLC
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Safe and effective anti CD154 antibodies for therapeutic intervention
Amount: $300,000.00DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
Amount: $600,000.00DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Preclinical Development of a Novel and Powerful Immunotherapeutic
Amount: $2,776,441.00DESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and ne ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
Amount: $537,514.00DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Not ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Potent Vaccine Adjuvant Therapeutic
Amount: $577,222.00DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have r ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Creation of an Anti-CD40 Superagonistic Monoclonal Antibody
Amount: $329,936.00Description: The overall goal of this revised SBIR application is to produce and test monoclonal antibodies (mab) to human CD40 that possess super-agonistic activity, as part of an adjuvant platfor ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health
